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Background: Multidrug resistant-tuberculosis (MDR-TB) is a
threat to global tuberculosis control which is worsened by human
immune-deﬁciency virus (HIV) co-infection. There is however
paucity of data on the effects of antiretroviral treatment (ART)
before or after starting MDR-TB treatment. This study determined
predictors of mortality and treatment failure among MDR-TB-HIV
co-infected patients on ART.
Methods & Materials: A retrospectivemedical record review of
1200 HIV co-infected MDR-TB patients admitted at Sizwe Tropical
Disease Hospital, Johannesburg from 2007 to 2010 was performed.
Chi-square test was used to determine treatment outcomes in
MDR-TB-HIV co-infected patients on ART. Multivariable logistic
regression and Poisson models were used to determine predictors
of mortality and treatment failure respectively.
Results: Mortality was higher (21.8% vs. 15.4%) among patients
who started ART before initiating MDR-TB treatment (p =0.013).
Factors signiﬁcantly associated with mortality included: the use of
ARTbefore startingMDR-TB treatment (OR1.65, 95%CI 1.002-2.73),
severely-underweight (OR3.71, 95%CI 1.89-7.29) andunderweight
(OR 2.35, 95% CI 1.30-4.26), cavities on chest x-rays at baseline (OR
1.76, 95% CI 1.08-2.94), presence of other opportunistic infections
(OR 1.80, 95% CI 1.10-2.94) and presence of other co-morbidities
(OR 2.26, 95% CI 1.20-4.21). Factors predicting failure were severe
anaemia (IRR (OR 4.72, 95% CI 1.47-15), other co-morbidities (OR
2.39, 95% CI 1.05-5.43) and individualised regimen at baseline (OR
2.15 95% CI 0.98-4.71).
Conclusion: High mortality among patients already on ART
before initiating MDR-TB treatment is a worrisome development.
Management of adverse-events, opportunistic infections and co-
morbidities in these patients is important if the protective beneﬁts
of being on ART are to be maximized. There is the need to intensify
intervention programmes targeted at early identiﬁcation of MDR-
TB, treatment initiation, drugmonitoring and increasing adherence
among HIV co-infected MDR-TB patients.
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Cellular iron status affects drug susceptibilities
and bioﬁlm formation of mycobacterium
R. Pal ∗, S. Hameed, Z. Fatima
Amity University Haryana, Gurgaon, Manesar, India
Background: Continuous and widespread usage of antituber-
cular drugs leading Multi-Drug Resistance (MDR) acquired by
Mycobacterium tuberculosis (MTB) demands immediate search for
novel targets andmechanisms. The ability ofMTB to adapt the hos-
tile environment is essential for its survival and confers the basis of
successful infection. A crucial condition that MTB must overcome
during the establishment of infection within the host is iron lim-
itation, since iron not freely available is required by both bacteria
and humans. This study aims to investigate the effect of iron depri-
vation on drug susceptibilities of known anti-TB drugs and bioﬁlm
formation in Mycobacterium smegmatis, a “surrogate of MTB.”
Methods & Materials: Drug susceptibility was tested using
brothmicrodilution todetermineminimal inhibitory concentration
(MIC) and spot assays under iron deprivation. Membrane perme-
ability and passive diffusion of drugs were assessed by nitroceﬁn
hydrolysis and EtBr efﬂux assays respectively. Membrane disrup-
tionwasalso studiedwith transmissionelectronmicroscopy (TEM).
Bioﬁlm formation was quantitatively measured with crystal violet
(CV) dye binding.
Results: The study revealed that iron deprivation led to
enhanced potency of the most commonly used ﬁrst line anti-
TB drugs that could be reverted upon iron supplementation.
It was explored that membrane homeostasis is disrupted upon
iron deprivation as revealed by enhanced membrane permeabil-
ity, hypersensitivity to membrane perturbing agent leading to
increased passive diffusion of drug and TEM images showing
detectable differences in cell envelope architecture. It was also
shown that hypoxia but not alkalinepHwhichmimics irondepriva-
tion also leads to enhanced potency of anti-TB drugs. Furthermore,
iron seems to be indispensable to sustain genotoxic stress sug-
gesting its possible role in DNA repair machinery. Finally, iron
deprivation also inhibits bioﬁlm formation which is an important
virulence attribute.
Conclusion: The study for the ﬁrst time established a link
between cellular iron, drug susceptibility and bioﬁlm of Mycobac-
terium suggesting iron as novel determinant to combat MDR.
http://dx.doi.org/10.1016/j.ijid.2016.02.862
